D. Gilligan

发表

A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.

U. Dafni, R. Stahel, S. Peters, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.

N. Pavlakis, T. Nakano, J. Aerts, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.

R. Kurek, T. Ruhstaller, D. Cunningham, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

The role of radiotherapy in the treatment of malignant pleural mesothelioma.

D. Gilligan, K. Waite, 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

Assessment and Optimisation of Lung Cancer Patients for Treatment with Curative Intent.

R. Rintoul, L. Williams, D. Gilligan, 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.

A. Hindmarsh, W. Qian, S. Prewett, 2015, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

Clinicians' Views of Educational Interventions for Carers of Patients With Breathlessness Due to Advanced Disease: Findings From an Online Survey.

M. Farquhar, G. Ewing, C. Penfold, 2017, Journal of pain and symptom management.

Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer

T. Eisen, D. Ferry, W. Qian, 2008, Thorax.

Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis.

A. Hackshaw, R. Rudd, N. Gower, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inaccurate clinical nodal staging of non-small cell lung cancer: evidence from the MRC LU22 multicentre randomised trial

H. Groen, M. Parmar, R. Stephens, 2010, Thorax.

Adjuvant chemotherapy in non-small cell lung cancer -- how feasible is it in a non-trial population?

S. Harden, D. Gilligan, S. Treece, 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial.

W. Ryder, R. Rintoul, C. Faivre-Finn, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hyper-Fractionated Radiotherapy for Soft Tissue Sarcoma: Results of the Second Study of Hyper-Fractionated Radiotherapy

C. Harmer, M. Robinson, D. Gilligan, 1999, Sarcoma.

Radical radiotherapy with or without gemcitabine in patients with early stage medically inoperable non-small cell lung cancer.

C. Faivre-Finn, A. Price, S. Erridge, 2012, Lung cancer.

Improving surgical resection rate in lung cancer

R. Coulden, C. Laroche, F. Wells, 1998, Thorax.

Six key topics informal carers of patients with breathlessness in advanced disease want to learn about and why: MRC phase I study to inform an educational intervention

M. Farquhar, G. Ewing, C. Penfold, 2017, PloS one.

Bronchoalveolar lavage in patients with mild and severe rheumatoid lung disease.

B. Bresnihan, K. Ward, C. O'connor, 1990, Thorax.

Complete pathological response to chemotherapy for non-small cell lung cancer demonstrated by gamma camera positron emission tomography.

R. Coulden, K. Balan, S. Old, 2000, Clinical oncology (Royal College of Radiologists (Great Britain)).

The use of ultrasound to measure breast thickness to select electron energies for breast boost radiotherapy.

J. Yarnold, J. Hendry, D. Gilligan, 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.

U. Dafni, R. Stahel, A. Addeo, 2022, Lung cancer.

Paraneoplastic limbic encephalitis attributable to thymoma.

D. Gilligan, M. Waters, M. Chaudhry, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

R. Stahel, H. Roschitzki-Voser, E. Nadal, 2019, Annals of Oncology.

Dosage of colloidal bismuth subcitrate in duodenal ulcer healing and clearance of Campylobacter pylori

C. O'Morain, L. Hutchinson, C. Keane, 1990, Alimentary pharmacology & therapeutics.

Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.

David Gilligan, S. Pacey, Simon Pacey, 2015, The Lancet. Oncology.

Genomic evidence supports a clonal diaspora model for metastases of esophageal 1 adenocarcinoma 2 3

Shalini, A. Hindmarsh, D. Wedge, 2019 .

Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinoma

M. Stratton, A. Hindmarsh, D. Wedge, 2018, bioRxiv.

Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis

Rebecca C Fitzgerald, Carlos Caldas, Arusha Oloumi, 2014, Nature Genetics.

Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial

S. Beck, J. Shamash, L. Butcher, 2017, JAMA oncology.

The National Lung Matrix Trial of personalized therapy in lung cancer

C. Swanton, N. O'Rourke, L. Billingham, 2020, Nature.

ctDNA detection by personalised assays in early-stage NSCLC

R. Rintoul, D. Gale, S. Harden, 2021, medRxiv.

A randomised phase III comparison of gemcitabine/carboplatin (GC) with cisplatin/etoposide (PE) in patients with poor prognosis small cell lung cancer (SCLC)

P. Ellis, T. Eisen, W. Gregory, 2002 .

Radical radiotherapy for 28 cases of mucosal melanoma in the nasal cavity and sinuses.

N. Slevin, D. Gilligan, 1991, The British journal of radiology.

Neutrophil-Lymphocyte Ratio and Absolute Lymphocyte Count as Prognostic Markers in Patients Treated with Curative-intent Radiotherapy for Non-small Cell Lung Cancer.

K. Blyth, C. Hiley, C. Faivre-Finn, 2021, Clinical oncology (Royal College of Radiologists (Great Britain)).

Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer.

A. Hackshaw, A. Price, P. Woll, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TREATMENT APPROACHES FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER THAT HAVE ACQUIRED RESISTANCE TO EGFR INHIBITORS

S. Pacey, D. Gilligan, C. Tan, 2015 .

Accelerated hypo-fractionated radiotherapy for non small cell lung cancer: results from 4 UK centres.

S. Harden, J. Lester, E. Hudson, 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1

S. Tavaré, P. Edwards, H. Barr, 2015, Scientific Reports.

Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer

R. Rintoul, D. Gale, S. Hackinger, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Predicting the Risk of Disease Recurrence and Death Following Curative-intent Radiotherapy for Non-small Cell Lung Cancer: The Development and Validation of Two Scoring Systems From a Large Multicentre UK Cohort.

K. Blyth, C. Hiley, C. Faivre-Finn, 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

Performance status score: do patients and their oncologists agree?

L. Sharples, S. Charman, S. Blagden, 2003, British Journal of Cancer.

The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer An Analysis Based on Individual Participant Data

H. Groen, M. Parmar, M. Tsuboi, 2018 .

Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review

O. Dalesio, H. Groen, M. Parmar, 2007, The Lancet.

The management of lung cancer: a UK survey of oncologists.

M. Williams, S. Prewett, D. Gilligan, 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).

ATOMIC-Meso: A randomized phase 2/3 trial of ADI-PEG20 or placebo with pemetrexed and cisplatin in patients with argininosuccinate synthetase 1-deficient non-epithelioid mesothelioma.

M. Zauderer, A. Mansfield, G. Ceresoli, 2017 .

A case of malignant mesothelioma in a young patient with childhood leukaemia who had received total body irradiation

A. Peryt, D. Gilligan, Zubair Khalid, 2023, Oxford medical case reports.

Clinical trials in lung cancer: evidence that a programmed investigation unit and a multidisciplinary clinic may improve recruitment.

C. Laroche, D. Gilligan, L. Magee, 2001, Clinical oncology (Royal College of Radiologists (Great Britain)).

Impact of pre-operative chemotherapy on the quality of life (QL) of patients with resectable non-small cell lung cancer (NSCLC): Experience from the MRC LU22/NVALT/EORTC 08012 multicentre randomised trial

R. Stephens, M. Nankivell, M. Nicolson, 2007 .

A phase III randomised comparison of gemcitabine/carboplatin (GC) with cisplatin/etoposide (PE) in patients with poor prognosis small cell lung cancer (SCLC

P. Ellis, T. Eisen, W. Gregory, 2002 .

RECENT DEVELOPMENTS IN THE DIAGNOSIS AND TREATMENT OF LUNG CANCER

D. Gilligan, 1998, International journal of clinical practice.

Author Correction: Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1

S. Tavaré, A. Hindmarsh, V. Sujendran, 2019, Scientific Reports.

Response of NOTCH1-Activated Tracheal Adenoid Cystic Carcinoma to the Gamma Secretase Inhibitor Nirogacestat

M. Hubank, G. Doherty, D. Gilligan, 2021, JCO Precision Oncology.

The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer

H. Groen, M. Parmar, M. Tsuboi, 2018, Chest.

OA 02.03 Prophylactic Irradiation of Tracts (PIT) in Patients with Pleural Mesothelioma: Results of a Multicenter Phase III Trial

R. Rintoul, C. Faivre-Finn, M. Peake, 2017 .

Sharing news of a lung cancer diagnosis with adult family members and friends: a qualitative study to inform a supportive intervention.

M. Farquhar, G. Ewing, J. Benson, 2016, Patient education and counseling.

Platelet satellitism

G. Follows, D. Gilligan, N. Grigoropoulos, 2010, European journal of haematology.

R. Kurek, T. Ruhstaller, M. Valladares-Ayerbes, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Bronchoalveolar lavage inpatients withmildand severerheumatoid lungdisease

B. Bresnihan, K. Ward, C. O'connor, 2011 .

Lung cancer in never-smokers: a hidden disease

M. Peake, P. Cosford, D. Gilligan, 2019, Journal of the Royal Society of Medicine.